Memini (Memantine Hydrochloride)

Memini is used in the management of Alzheimer's disease, acting on glutamatergic neurotransmission to help preserve cognitive function.

• Alzheimer's disease (moderate to severe): may improve cognition and daily functioning.
• Alzheimer's disease (mild to moderate) as adjunct therapy: can provide additional benefit when combined with cholinesterase inhibitors.
• Behavioral symptoms in Alzheimer's disease: may reduce agitation and improve patient cooperation.

• Memantine Hydrochloride binds to the NMDA receptor channel at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By blocking excessive calcium influx caused by overstimulation of the receptor, it reduces glutamate‑mediated excitotoxicity, which is implicated in neuronal damage associated with Alzheimer's disease.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient cranial discomfort.
• Constipation: reduced bowel movements.
• Confusion: temporary mental clouding.
• Fatigue: increased tiredness.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythm potentially serious.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome: rare skin disorder with blistering.

Memini should be used with caution in specific clinical situations.

• Renal impairment: assess kidney function and adjust therapy if needed.
• Hepatic impairment: monitor liver enzymes during treatment.
• History of seizures: evaluate risk and consider alternative therapy.
• Concurrent NMDA antagonists: avoid combined use to prevent additive neurotoxicity.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Memini may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Other NMDA antagonists (e.g., ketamine): heightened risk of central nervous system effects.
• Strong CYP450 inducers (e.g., carbamazepine): may lower memantine plasma concentrations.
• Anticholinergic agents: can worsen cognitive impairment.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effects.
• Antihypertensives: monitor blood pressure for additive lowering.
• Anticholinesterase inhibitors: observe for changes in therapeutic response.